SNPHF News Alert Santen Pharmaceutica (SNPHF) 63.2000 02/15/2015
Post# of 64074
Posted On: 02/15/2015 2:33:04 PM
Santen Pharmaceutica (SNPHF) 63.2000 $SNPHF
Glaucoma Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Sun Jan 25, 11:30AM CST
The report "Glaucoma - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Glaucoma. Glaucoma is caused because of the pressure inside the eye. The primary function of the optic nerve is to send images to the brain. Permanent loss of vision can occur if this optic nerve gets damaged. If not treated on time total permanent blindness might occur. Proper precautions (like visiting an eye doctor) must be taken. The disease can be inherited and if any member of the family is found to be having glaucoma then immediately go for checking. Complete Report is Available @ http://www.rnrmarketresearch.com/glaucoma-pip...eport.html .
ITEK: (), NBS: 3.78 (+0.14), FOMX: 9.01 (-0.03), AERI: 27.91 (+0.14), OCUL: 31.25 (-0.01), AGN: 229.49 (+1.87), CANF: 3.85 (+0.05), ACAD: 34.21 (+0.37), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), TEVA: 56.77 (-0.58), OHRP: 7.38 (-0.30), CBMG: 24.32 (-1.17)
DURECT Enters into License Agreement Granting Santen the Worldwide Rights to a Sustained Release SABER® Ophthalmology Product
PR Newswire - Tue Dec 16, 7:00AM CST
DURECT Corporation (Nasdaq: DRRX) announced today that it has entered into an agreement with Santen Pharmaceutical Co., Ltd. granting Santen the exclusive worldwide rights to develop and commercialize a sustained release product utilizing DURECT's SABER® technology to deliver an ophthalmology drug.
DRRX: 1.00 (+0.03)
Increase of Capital for a Consolidated Subsidiary in Europe
GlobeNewswire - Thu Sep 25, 4:32AM CDT
Santen Pharmaceutical Co., Ltd. (Osaka, hereinafter "Santen"
hereby announces that it was resolved at the Board of Director meeting held on September 25, 2014 to increase capital for Santen Holdings EU B.V., a consolidated wholly owned holding company in Europe.
Global Open-Angle Glaucoma Therapeutics Pipeline Review 2014 - 22 Drug Profiles from 11 Companies
M2 - Fri Sep 12, 3:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c97xhn/openangle) has announced the addition of the "Open-Angle Glaucoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Open-Angle Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Open-Angle Glaucoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Bausch & Lomb Incorporated - Santen Pharmaceutical Co., Ltd. - Oxford BioMedica plc - Sylentis S.A. - Ono Pharmaceutical Co., Ltd. - Asahi Kasei Pharma Corp. - Inotek Pharmaceuticals Corporation - Aerie Pharmaceuticals, Inc. - Otsuka Holdings Co., Ltd. - Amakem NV Drug Profiles - tafluprost - (tafluprost timolol maleate) - latanoprostene bunod - latanoprost - OPC-1085EL - trabodenoson - SYL-040012 - RO-5093151 - latanoprost - AR-13324 - AMA-0076 - ONO-9054 - ATS-907 - DE-117 - (latanoprost dorzolamide) - LX-7101 - HPP-851 - OPA-6566 - latanoprost SR - Glaucoma-GT - ATS-8535 - Small Molecule for Glaucoma For more information visit http://www.researchandmarkets.com/research/c97xhn/openangle
AERI: 27.91 (+0.14)
Uveitis Therapeutics Pipeline Review, H2 2014 - 19 Companies & 30 Drug Profiles
M2 - Tue Sep 09, 8:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cv63wn/uveitis) has announced the addition of the "Uveitis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Uveitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Uveitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - pSivida Corp. - Advanced Cell Technology, Inc. - Santen Pharmaceutical Co., Ltd. - Apitope International NV - Novartis AG - Pfizer Inc. - Enzo Biochem, Inc. - Can-Fite BioPharma Ltd. - XOMA Corporation - HanAll Biopharma Co., Ltd. - TxCell SA - Endocyte, Inc. - to-BBB technologies BV - Janssen Biotech, Inc. - Icon Bioscience, Inc. - Eleven Biotherapeutics - AbbVie Inc. - OncoNOx ApS - Panoptes Pharma Ges.m.b.H. Drug Profiles - sirolimus - adalimumab - fluocinolone acetonide - gevokizumab - secukinumab - CF-101 - triamcinolone acetonide - LFG-316 - B27-PD - triamcinolone acetonide - celecoxib - HL-036 - EC-1496 - PA-2612 - 2B3-201 - ATX-UV1 - ATX-UV2 - Stem Cell Therapy for Ophthalmic and Autoimmune Diseases - OX-1001 - P-13 - IBI-70090 - plastoquinone decyl triphenylphosphonium bromide - EC-1669 - lodamin - PP-001 - INV-17 - EBI-028 - Col-Treg - Small Molecules to Inhibit Kinase for Uveitis and IBD - Drugs to Inhibit Aldose Reductase for Immunology, Ophthalmology, Metabolic, Respiratory and Autoimmune Disorders For more information visit http://www.researchandmarkets.com/research/cv63wn/uveitis
CANF: 3.85 (+0.05), ECYT: 5.26 (-0.02), ENZ: 3.12 (-0.18), PFE: 34.64 (-0.23), ABBV: 58.05 (+1.00), XOMA: 3.41 (-0.01), NVS: 102.20 (-0.17)
Global Macular Edema Market 2014-2018 with Bayer AG, F. Hoffmann-La Roche, Novartis & Regeneron Pharmaceuticals Dominating
M2 - Tue Aug 12, 6:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6chxqf/global_macular) has announced the addition of the "Global Macular Edema Market 2014-2018" report to their offering. The Global Macular Edema market will grow at a CAGR of 9.1% over the period 2014-2018. NICE issues and updates technology appraisals and clinical guidelines to recommend appropriate and effective treatments for different diseases. It plays a role in increasing drug sales. In January 2013, NICE recommended Lucentis for the treatment of DME. This recommendation superseded the November 2011 guidance, which concluded that recommending Lucentis was not effective utilization of NHS resources. Lucentis has also been recommended for the treatment of vision impairment as a result of macular edema associated with RVO According to the report, the Global Macular Edema market is driven by several factors, of which the increase in the patient population is one of the major drivers. Eye diseases such as DR, retinal dystrophies, AMD, inflammatory conditions such as uveitis, and RVO cause macular edema. The increase in the incidence and prevalence of ophthalmological conditions such as AMD and DR is expected to increase the patient population with macular edema during the forecast period. Further, the report states that although the Global Macular Edema market has several drivers, the growth of the market is curtailed by some serious challenges. One of the main challenges is increased use of off-label drugs. Use of off-label drugs increases the market competition for approved branded drugs. Some of the off-label drugs for the treatment of macular edema are bevacizumab, topical NSAIDs, and drugs such as acetazolamide. The report also includes a discussion of the other vendors operating in this market. The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. Key Vendors - Bayer AG - F. Hoffmann-La Roche Ltd. - Novartis AG - Regeneron Pharmaceuticals Inc. Other Prominent Vendors - Alcon Inc. - Alimera Sciences Inc. - Allergan Inc. - Ampio Pharmaceuticals Inc. - iCo Therapeutics Inc. - Pfizer Inc. - Santen Pharmaceutical Co. Ltd. For more information visit http://www.researchandmarkets.com/research/6c...al_macular
AGN: 229.49 (+1.87), ALIM: 5.16 (unch), PFE: 34.64 (-0.23), AMPE: 5.85 (-0.05), REGN: 402.40 (+0.66), NVS: 102.20 (-0.17)
Global Retinal Vein Occlusion Market 2014-2018: Key Vendors are Bayer, F. Hoffmann-La Roche, Novartis and Regeneron Pharmaceuticals
M2 - Wed Jul 30, 5:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rqg93q/global_retinal) has announced the addition of the "Global Retinal Vein Occlusion Market 2014-2018" report to their offering. Retinal vein occlusion is a medical condition where there is a blockage in the retinal veins. This blocks the flow of blood in the retina, which can damage the nerve cells of the eye and result in loss of vision. Retinal vein occlusion can occur as a result of a clot in a vein, especially if the veins of the eye are very narrow. The disease is likely to affect people who are already suffering from hypertension, diabetes mellitus, or hyperlipidaemia. Retinal vein occlusion is one of the most common causes of blindness after diabetic retinopathy. It is also one of the most common vascular disorders of the eye. Retinal vein occlusion can be broadly classified into two types, central retinal vein occlusion and branch retinal vein occlusion, with the latter being more frequent. Central retinal vein occlusion can be divided into two further subtypes, ischemic central retinal vein occlusion and non-ischemic central retinal vein occlusion. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Pipeline Portfolio 08. Rate of Incidence and Prevalence 09. Market Segmentation by Type of Therapy 10. Market Segmentation by Route of Administration 11. Market Segmentation by Dosage Forms 12. Geographical Segmentation 13. Buying Criteria 14. Market Growth Drivers 15. Drivers and their Impact 16. Market Challenges 17. Impact of Drivers and Challenges 18. Market Trends 19. Trends and their Impact 20. Vendor Landscape 21. Key Vendor Analysis 22. Other Reports in this Series Companies Mentioned: - Bayer AG - F. Hoffmann-La Roche Ltd. - Novartis AG - Regeneron Pharmaceuticals Inc. - Alimera Sciences - Bristol-Myers Squibb - NicOx - Santen Pharmaceutical Co. - Valeant Pharmaceuticals International For more information visit http://www.researchandmarkets.com/research/rq...al_retinal
ALIM: 5.16 (unch), BMY: 60.04 (+0.56), REGN: 402.40 (+0.66), VRX.TO: 207.95 (-1.47), NVS: 102.20 (-0.17)
Santen Pharmaceutical Facilitates Compliance, Promotes Safety, and Supports Growth with Oracle Argus Cloud Service
M2 - Tue Jul 08, 8:30AM CDT
Santen Pharmaceutical Co., Ltd. (Santen), a Japan-based pharmaceutical company specializing in ophthalmic and anti-rheumatoid arthritis products, wanted to centralize its pharmacovigilance and medical device safety processes to increase visibility into drug safety data and global regulatory compliance. To achieve those goals while maintaining high availability and gaining a predictable IT spend, the company deployed Oracle Argus Cloud Service . Working with Oracle Health Sciences Consulting, the pharmaceutical company was live on the solution in just 10 months.
ORCL: 43.93 (+0.04)
Santen Announces Closing of Asset Purchase Agreement With Respect to Acquisition of Ophthalmology Assets From Merck
GlobeNewswire - Wed Jul 02, 1:33AM CDT
Santen Pharmaceutical Co., Ltd. (Osaka, Japan) (Santen) announced the closing of an asset purchase agreement ("Agreement" which was entered on May 13, 2014 between Merck & Co., Inc. (Whitehouse Station, NJ, USA, known as MSD outside of the U.S.A and Canada) (Merck) with respect to the acquisition of certain ophthalmology assets, following the fulfillment of all of the transfer conditions, except in some territories, in accordance with the terms of the Agreement. Accordingly, on July 1, 2014 (US-ET), Santen completed the payment to Merck as stated below.
MRK: 58.81 (-0.07)
Global Uveitis Market 2014-2018
M2 - Mon Jun 23, 4:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3f25wz/global_uveitis) has announced the addition of the "Global Uveitis Market 2014-2018" report to their offering. Currently, the current competition in the Global Uveitis market is weak and the available treatment options have only been moderately successful in meeting market demand. The current market is served in the main by three approved products namely Alcon Laboratories's Durezol, Allergan's Ozurdex, and Bausch & Lomb's Retisert. The expected entry of new players such as Lux Biosciences's Luveniq (NDA filled), pSivida Corp.'s Medidur (phase III), and Santen Pharmaceutical Co. Ltd.'s DE-109 (phase III) within the forecast period is expected to intensify the competition in future. The products currently available in the market are associated with low safety and as those products do not serve the market's unmet need, the market continues to present opportunities for stronger pipeline candidates. According to the report, one of the main drivers in this market is the increasing prevalence of eye disorders around the world, which has consequently led to a rise in the incidence of uveitis. Uveitis is responsible for approximately 5 to 20 percent of legal blindness in western countries and approximately 25 percent of blindness in the developing world. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Product Profiles 05. Market Research Methodology 06. Introduction 07. Market Landscape 08. Treatment Options for Uveitis 09. Pipeline Snapshot 10. Rate of Incidence and Prevalence 11. Geographical Segmentation 12. Buying Criteria 13. Market Growth Drivers 14. Drivers and their Impact 15. Market Challenges 16. Impact of Drivers and Challenges 17. Market Trends 18. Trends and their Impact 19. Vendor Landscape 20. Key Vendor Analysis 21. Other Reports in this Series Companies Mentioned: - Abbvie Inc. - Alcon Laboratories Inc. - Allergan Inc. - Bausch & Lomb Inc. - Artielle ImmunoTherapeutics Inc. - Enzo Biochem Inc. - Hanall Pharmaceutical Co. Ltd. - Lux Biosciences Inc. - OphthaliX Inc. - Regeneron Pharmaceuticals Inc. - TopiVertLtd. - pSivida Corp. - XOMA Corp. - Santen Pharmaceutical Co. For more information visit http://www.researchandmarkets.com/research/3f...al_uveitis
AGN: 229.49 (+1.87), ENZ: 3.12 (-0.18), REGN: 402.40 (+0.66), XOMA: 3.41 (-0.01)
Ocular Hypertension - Pipeline Review, H1 2014
M2 - Mon Jun 16, 5:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bzfhkc/ocular) has announced the addition of the "Ocular Hypertension - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Ocular Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ocular Hypertension and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Alcon, Inc. - F. Hoffmann-La Roche Ltd. - Bausch & Lomb Incorporated - Allergan, Inc. - Santen Pharmaceutical Co., Ltd. - Sylentis S.A. - Kowa Company, Ltd. - Ono Pharmaceutical Co., Ltd. - Sun Pharmaceutical Industries Limited - Can-Fite BioPharma Ltd. - Lexicon Pharmaceuticals, Inc. - Laboratoires Thea S.A. - Asahi Kasei Pharma Corp. - Inotek Pharmaceuticals Corporation - Aerie Pharmaceuticals, Inc. - D. Western Therapeutics Institute, Inc. - Icon Bioscience, Inc. - Otsuka Holdings Co., Ltd. - Ocular Therapeutix, Inc. - Amakem NV - High Point Pharmaceuticals, LLC For more information visit http://www.researchandmarkets.com/research/bzfhkc/ocular
CANF: 3.85 (+0.05), AGN: 229.49 (+1.87), LXRX: 0.89 (unch), AERI: 27.91 (+0.14)
Glaucoma Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Sun Jan 25, 11:30AM CST
The report "Glaucoma - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Glaucoma. Glaucoma is caused because of the pressure inside the eye. The primary function of the optic nerve is to send images to the brain. Permanent loss of vision can occur if this optic nerve gets damaged. If not treated on time total permanent blindness might occur. Proper precautions (like visiting an eye doctor) must be taken. The disease can be inherited and if any member of the family is found to be having glaucoma then immediately go for checking. Complete Report is Available @ http://www.rnrmarketresearch.com/glaucoma-pip...eport.html .
ITEK: (), NBS: 3.78 (+0.14), FOMX: 9.01 (-0.03), AERI: 27.91 (+0.14), OCUL: 31.25 (-0.01), AGN: 229.49 (+1.87), CANF: 3.85 (+0.05), ACAD: 34.21 (+0.37), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), TEVA: 56.77 (-0.58), OHRP: 7.38 (-0.30), CBMG: 24.32 (-1.17)
DURECT Enters into License Agreement Granting Santen the Worldwide Rights to a Sustained Release SABER® Ophthalmology Product
PR Newswire - Tue Dec 16, 7:00AM CST
DURECT Corporation (Nasdaq: DRRX) announced today that it has entered into an agreement with Santen Pharmaceutical Co., Ltd. granting Santen the exclusive worldwide rights to develop and commercialize a sustained release product utilizing DURECT's SABER® technology to deliver an ophthalmology drug.
DRRX: 1.00 (+0.03)
Increase of Capital for a Consolidated Subsidiary in Europe
GlobeNewswire - Thu Sep 25, 4:32AM CDT
Santen Pharmaceutical Co., Ltd. (Osaka, hereinafter "Santen"
hereby announces that it was resolved at the Board of Director meeting held on September 25, 2014 to increase capital for Santen Holdings EU B.V., a consolidated wholly owned holding company in Europe. Global Open-Angle Glaucoma Therapeutics Pipeline Review 2014 - 22 Drug Profiles from 11 Companies
M2 - Fri Sep 12, 3:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c97xhn/openangle) has announced the addition of the "Open-Angle Glaucoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Open-Angle Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Open-Angle Glaucoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Bausch & Lomb Incorporated - Santen Pharmaceutical Co., Ltd. - Oxford BioMedica plc - Sylentis S.A. - Ono Pharmaceutical Co., Ltd. - Asahi Kasei Pharma Corp. - Inotek Pharmaceuticals Corporation - Aerie Pharmaceuticals, Inc. - Otsuka Holdings Co., Ltd. - Amakem NV Drug Profiles - tafluprost - (tafluprost timolol maleate) - latanoprostene bunod - latanoprost - OPC-1085EL - trabodenoson - SYL-040012 - RO-5093151 - latanoprost - AR-13324 - AMA-0076 - ONO-9054 - ATS-907 - DE-117 - (latanoprost dorzolamide) - LX-7101 - HPP-851 - OPA-6566 - latanoprost SR - Glaucoma-GT - ATS-8535 - Small Molecule for Glaucoma For more information visit http://www.researchandmarkets.com/research/c97xhn/openangle
AERI: 27.91 (+0.14)
Uveitis Therapeutics Pipeline Review, H2 2014 - 19 Companies & 30 Drug Profiles
M2 - Tue Sep 09, 8:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cv63wn/uveitis) has announced the addition of the "Uveitis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Uveitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Uveitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - pSivida Corp. - Advanced Cell Technology, Inc. - Santen Pharmaceutical Co., Ltd. - Apitope International NV - Novartis AG - Pfizer Inc. - Enzo Biochem, Inc. - Can-Fite BioPharma Ltd. - XOMA Corporation - HanAll Biopharma Co., Ltd. - TxCell SA - Endocyte, Inc. - to-BBB technologies BV - Janssen Biotech, Inc. - Icon Bioscience, Inc. - Eleven Biotherapeutics - AbbVie Inc. - OncoNOx ApS - Panoptes Pharma Ges.m.b.H. Drug Profiles - sirolimus - adalimumab - fluocinolone acetonide - gevokizumab - secukinumab - CF-101 - triamcinolone acetonide - LFG-316 - B27-PD - triamcinolone acetonide - celecoxib - HL-036 - EC-1496 - PA-2612 - 2B3-201 - ATX-UV1 - ATX-UV2 - Stem Cell Therapy for Ophthalmic and Autoimmune Diseases - OX-1001 - P-13 - IBI-70090 - plastoquinone decyl triphenylphosphonium bromide - EC-1669 - lodamin - PP-001 - INV-17 - EBI-028 - Col-Treg - Small Molecules to Inhibit Kinase for Uveitis and IBD - Drugs to Inhibit Aldose Reductase for Immunology, Ophthalmology, Metabolic, Respiratory and Autoimmune Disorders For more information visit http://www.researchandmarkets.com/research/cv63wn/uveitis
CANF: 3.85 (+0.05), ECYT: 5.26 (-0.02), ENZ: 3.12 (-0.18), PFE: 34.64 (-0.23), ABBV: 58.05 (+1.00), XOMA: 3.41 (-0.01), NVS: 102.20 (-0.17)
Global Macular Edema Market 2014-2018 with Bayer AG, F. Hoffmann-La Roche, Novartis & Regeneron Pharmaceuticals Dominating
M2 - Tue Aug 12, 6:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6chxqf/global_macular) has announced the addition of the "Global Macular Edema Market 2014-2018" report to their offering. The Global Macular Edema market will grow at a CAGR of 9.1% over the period 2014-2018. NICE issues and updates technology appraisals and clinical guidelines to recommend appropriate and effective treatments for different diseases. It plays a role in increasing drug sales. In January 2013, NICE recommended Lucentis for the treatment of DME. This recommendation superseded the November 2011 guidance, which concluded that recommending Lucentis was not effective utilization of NHS resources. Lucentis has also been recommended for the treatment of vision impairment as a result of macular edema associated with RVO According to the report, the Global Macular Edema market is driven by several factors, of which the increase in the patient population is one of the major drivers. Eye diseases such as DR, retinal dystrophies, AMD, inflammatory conditions such as uveitis, and RVO cause macular edema. The increase in the incidence and prevalence of ophthalmological conditions such as AMD and DR is expected to increase the patient population with macular edema during the forecast period. Further, the report states that although the Global Macular Edema market has several drivers, the growth of the market is curtailed by some serious challenges. One of the main challenges is increased use of off-label drugs. Use of off-label drugs increases the market competition for approved branded drugs. Some of the off-label drugs for the treatment of macular edema are bevacizumab, topical NSAIDs, and drugs such as acetazolamide. The report also includes a discussion of the other vendors operating in this market. The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. Key Vendors - Bayer AG - F. Hoffmann-La Roche Ltd. - Novartis AG - Regeneron Pharmaceuticals Inc. Other Prominent Vendors - Alcon Inc. - Alimera Sciences Inc. - Allergan Inc. - Ampio Pharmaceuticals Inc. - iCo Therapeutics Inc. - Pfizer Inc. - Santen Pharmaceutical Co. Ltd. For more information visit http://www.researchandmarkets.com/research/6c...al_macular
AGN: 229.49 (+1.87), ALIM: 5.16 (unch), PFE: 34.64 (-0.23), AMPE: 5.85 (-0.05), REGN: 402.40 (+0.66), NVS: 102.20 (-0.17)
Global Retinal Vein Occlusion Market 2014-2018: Key Vendors are Bayer, F. Hoffmann-La Roche, Novartis and Regeneron Pharmaceuticals
M2 - Wed Jul 30, 5:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rqg93q/global_retinal) has announced the addition of the "Global Retinal Vein Occlusion Market 2014-2018" report to their offering. Retinal vein occlusion is a medical condition where there is a blockage in the retinal veins. This blocks the flow of blood in the retina, which can damage the nerve cells of the eye and result in loss of vision. Retinal vein occlusion can occur as a result of a clot in a vein, especially if the veins of the eye are very narrow. The disease is likely to affect people who are already suffering from hypertension, diabetes mellitus, or hyperlipidaemia. Retinal vein occlusion is one of the most common causes of blindness after diabetic retinopathy. It is also one of the most common vascular disorders of the eye. Retinal vein occlusion can be broadly classified into two types, central retinal vein occlusion and branch retinal vein occlusion, with the latter being more frequent. Central retinal vein occlusion can be divided into two further subtypes, ischemic central retinal vein occlusion and non-ischemic central retinal vein occlusion. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Pipeline Portfolio 08. Rate of Incidence and Prevalence 09. Market Segmentation by Type of Therapy 10. Market Segmentation by Route of Administration 11. Market Segmentation by Dosage Forms 12. Geographical Segmentation 13. Buying Criteria 14. Market Growth Drivers 15. Drivers and their Impact 16. Market Challenges 17. Impact of Drivers and Challenges 18. Market Trends 19. Trends and their Impact 20. Vendor Landscape 21. Key Vendor Analysis 22. Other Reports in this Series Companies Mentioned: - Bayer AG - F. Hoffmann-La Roche Ltd. - Novartis AG - Regeneron Pharmaceuticals Inc. - Alimera Sciences - Bristol-Myers Squibb - NicOx - Santen Pharmaceutical Co. - Valeant Pharmaceuticals International For more information visit http://www.researchandmarkets.com/research/rq...al_retinal
ALIM: 5.16 (unch), BMY: 60.04 (+0.56), REGN: 402.40 (+0.66), VRX.TO: 207.95 (-1.47), NVS: 102.20 (-0.17)
Santen Pharmaceutical Facilitates Compliance, Promotes Safety, and Supports Growth with Oracle Argus Cloud Service
M2 - Tue Jul 08, 8:30AM CDT
Santen Pharmaceutical Co., Ltd. (Santen), a Japan-based pharmaceutical company specializing in ophthalmic and anti-rheumatoid arthritis products, wanted to centralize its pharmacovigilance and medical device safety processes to increase visibility into drug safety data and global regulatory compliance. To achieve those goals while maintaining high availability and gaining a predictable IT spend, the company deployed Oracle Argus Cloud Service . Working with Oracle Health Sciences Consulting, the pharmaceutical company was live on the solution in just 10 months.
ORCL: 43.93 (+0.04)
Santen Announces Closing of Asset Purchase Agreement With Respect to Acquisition of Ophthalmology Assets From Merck
GlobeNewswire - Wed Jul 02, 1:33AM CDT
Santen Pharmaceutical Co., Ltd. (Osaka, Japan) (Santen) announced the closing of an asset purchase agreement ("Agreement"
which was entered on May 13, 2014 between Merck & Co., Inc. (Whitehouse Station, NJ, USA, known as MSD outside of the U.S.A and Canada) (Merck) with respect to the acquisition of certain ophthalmology assets, following the fulfillment of all of the transfer conditions, except in some territories, in accordance with the terms of the Agreement. Accordingly, on July 1, 2014 (US-ET), Santen completed the payment to Merck as stated below. MRK: 58.81 (-0.07)
Global Uveitis Market 2014-2018
M2 - Mon Jun 23, 4:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3f25wz/global_uveitis) has announced the addition of the "Global Uveitis Market 2014-2018" report to their offering. Currently, the current competition in the Global Uveitis market is weak and the available treatment options have only been moderately successful in meeting market demand. The current market is served in the main by three approved products namely Alcon Laboratories's Durezol, Allergan's Ozurdex, and Bausch & Lomb's Retisert. The expected entry of new players such as Lux Biosciences's Luveniq (NDA filled), pSivida Corp.'s Medidur (phase III), and Santen Pharmaceutical Co. Ltd.'s DE-109 (phase III) within the forecast period is expected to intensify the competition in future. The products currently available in the market are associated with low safety and as those products do not serve the market's unmet need, the market continues to present opportunities for stronger pipeline candidates. According to the report, one of the main drivers in this market is the increasing prevalence of eye disorders around the world, which has consequently led to a rise in the incidence of uveitis. Uveitis is responsible for approximately 5 to 20 percent of legal blindness in western countries and approximately 25 percent of blindness in the developing world. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Product Profiles 05. Market Research Methodology 06. Introduction 07. Market Landscape 08. Treatment Options for Uveitis 09. Pipeline Snapshot 10. Rate of Incidence and Prevalence 11. Geographical Segmentation 12. Buying Criteria 13. Market Growth Drivers 14. Drivers and their Impact 15. Market Challenges 16. Impact of Drivers and Challenges 17. Market Trends 18. Trends and their Impact 19. Vendor Landscape 20. Key Vendor Analysis 21. Other Reports in this Series Companies Mentioned: - Abbvie Inc. - Alcon Laboratories Inc. - Allergan Inc. - Bausch & Lomb Inc. - Artielle ImmunoTherapeutics Inc. - Enzo Biochem Inc. - Hanall Pharmaceutical Co. Ltd. - Lux Biosciences Inc. - OphthaliX Inc. - Regeneron Pharmaceuticals Inc. - TopiVertLtd. - pSivida Corp. - XOMA Corp. - Santen Pharmaceutical Co. For more information visit http://www.researchandmarkets.com/research/3f...al_uveitis
AGN: 229.49 (+1.87), ENZ: 3.12 (-0.18), REGN: 402.40 (+0.66), XOMA: 3.41 (-0.01)
Ocular Hypertension - Pipeline Review, H1 2014
M2 - Mon Jun 16, 5:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bzfhkc/ocular) has announced the addition of the "Ocular Hypertension - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Ocular Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ocular Hypertension and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Alcon, Inc. - F. Hoffmann-La Roche Ltd. - Bausch & Lomb Incorporated - Allergan, Inc. - Santen Pharmaceutical Co., Ltd. - Sylentis S.A. - Kowa Company, Ltd. - Ono Pharmaceutical Co., Ltd. - Sun Pharmaceutical Industries Limited - Can-Fite BioPharma Ltd. - Lexicon Pharmaceuticals, Inc. - Laboratoires Thea S.A. - Asahi Kasei Pharma Corp. - Inotek Pharmaceuticals Corporation - Aerie Pharmaceuticals, Inc. - D. Western Therapeutics Institute, Inc. - Icon Bioscience, Inc. - Otsuka Holdings Co., Ltd. - Ocular Therapeutix, Inc. - Amakem NV - High Point Pharmaceuticals, LLC For more information visit http://www.researchandmarkets.com/research/bzfhkc/ocular
CANF: 3.85 (+0.05), AGN: 229.49 (+1.87), LXRX: 0.89 (unch), AERI: 27.91 (+0.14)
(0)
(0)Scroll down for more posts ▼